FDA Approves Zidesamtinib for Pretreated ROS1-Positive NSCLC | Oncology Nursing News

FDA approved zidesamtinib (Jideytro), a next-generation ROS1 inhibitor, for metastatic ROS1-positive NSCLC in patients previously treated with kinase inhibitors, two months ahead of schedule. The ARROS-1 trial showed 44% objective response rate with durable responses in heavily pretreated patients, including those with brain metastases and resistance mutations.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.